These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 22152511)

  • 1. Platelets and endothelium: two key players in percutaneous coronary intervention.
    Bonello L; Sabatier F; Camoin-Jau L; Paganelli F; Dignat-George F
    Arch Cardiovasc Dis; 2011 Dec; 104(12):601-3. PubMed ID: 22152511
    [No Abstract]   [Full Text] [Related]  

  • 2. New directions in antiplatelet therapy.
    Ferreiro JL; Angiolillo DJ
    Circ Cardiovasc Interv; 2012 Jun; 5(3):433-45. PubMed ID: 22715450
    [No Abstract]   [Full Text] [Related]  

  • 3. Two-year follow-up of the Genous™ endothelial progenitor cell capturing stent versus the Taxus Liberté stent in patients with de novo coronary artery lesions with a high-risk of restenosis: a randomized, single-center, pilot study.
    Beijk MA; Klomp M; van Geloven N; Koch KT; Henriques JP; Baan J; Vis MM; Tijssen JG; Piek JJ; de Winter RJ
    Catheter Cardiovasc Interv; 2011 Aug; 78(2):189-95. PubMed ID: 21542109
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative analysis of neointimal coverage with paclitaxel and zotarolimus drug-eluting stents, using optical coherence tomography 6 months after implantation.
    Motreff P; Souteyrand G; Levesque S; Ouchchane L; Dauphin C; Sarry L; Cassagnes J; Lusson JR
    Arch Cardiovasc Dis; 2009; 102(8-9):617-24. PubMed ID: 19786265
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rationale and design of the randomized, multicenter EREMUS trial, a study that investigates how to achieve low restenosis and early reendothelialization after percutaneous coronary interventions.
    Cortese B; Danzi GB; Pitì A; Severi S; Limbruno U
    Catheter Cardiovasc Interv; 2011 Jul; 78(1):32-7. PubMed ID: 21413116
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New technologies in percutaneous coronary interventions: drug-coated balloons.
    Kleber FX; Scheller B; Serruys PW
    EuroIntervention; 2011 May; 7 Suppl K():K7. PubMed ID: 22027732
    [No Abstract]   [Full Text] [Related]  

  • 7. Engineering a bioresorbable stent: REVA programme update.
    Pollman MJ
    EuroIntervention; 2009 Dec; 5 Suppl F():F54-7. PubMed ID: 22100677
    [No Abstract]   [Full Text] [Related]  

  • 8. Vascular restoration therapy: the fourth revolution in interventional cardiology and the ultimate "rosy" prophecy.
    Wykrzykowska JJ; Onuma Y; Serruys PW
    EuroIntervention; 2009 Dec; 5 Suppl F():F7-8. PubMed ID: 22100680
    [No Abstract]   [Full Text] [Related]  

  • 9. Drug-eluting stent thrombosis: an oversensationalized but unresolved problem?
    Latib A; Chieffo A; Colombo A
    Monaldi Arch Chest Dis; 2007 Mar; 68(1):1-5. PubMed ID: 17564287
    [No Abstract]   [Full Text] [Related]  

  • 10. Stent thrombosis--risk assessment and prevention.
    Motovska Z; Knot J; Widimsky P
    Cardiovasc Ther; 2010 Oct; 28(5):e92-100. PubMed ID: 20553282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Very late scaffold thrombosis: insights from optical coherence tomography and histopathology.
    Joner M; Nicol P; Rai H; Richter H; Foin N; Ng J; Cuesta J; Rivero F; Serrano R; Alfonso F
    EuroIntervention; 2018 Apr; 13(18):e2169-e2173. PubMed ID: 29155382
    [No Abstract]   [Full Text] [Related]  

  • 12. Understanding the role of endothelial progenitor cells in cardiovascular disease, coronary artery lesion progression, and in-stent restenosis.
    De Winter RJ; Klomp M
    JACC Cardiovasc Interv; 2010 Jan; 3(1):87-9. PubMed ID: 20129575
    [No Abstract]   [Full Text] [Related]  

  • 13. Antiplatelet therapy in the era of percutaneous coronary intervention with drug-eluting balloons.
    Bonaventura K; Sonntag S; Kleber FX
    EuroIntervention; 2011 May; 7 Suppl K():K106-11. PubMed ID: 22027718
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Influence of residual stenosis after coronary stent implantation on development of restenosis and stent thrombosis.
    Colombo A
    Am J Cardiol; 2003 Oct; 92(8):1013; author reply 1013-4. PubMed ID: 14556889
    [No Abstract]   [Full Text] [Related]  

  • 15. Spatial distribution of neo-intimal hyperplasia 6 months after zotarolimus-eluting stent implantation, analysed by optical coherence tomography.
    Souteyrand G; Levesque S; Ouchchane L; Sarry L; Eschalier R; Lusson JR; Motreff P
    Arch Cardiovasc Dis; 2011 Mar; 104(3):147-54. PubMed ID: 21497303
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rotational atherectomy with drug-eluting stents: a necessary technique in the current era.
    Lozano I; Rondan J; Avanzas P
    Catheter Cardiovasc Interv; 2011 Jan; 77(1):160; author reply 161. PubMed ID: 21069801
    [No Abstract]   [Full Text] [Related]  

  • 17. Clinical outcomes after multilesion percutaneous coronary intervention: comparison between exclusive and selective use of drug-eluting stents.
    Bertrand OF; Faurie B; Larose E; Nguyen CM; Gleeton O; Déry JP; Noël B; Proulx G; Roy L; Costerousse O; De Larochellière R; Rodés-Cabau J
    J Invasive Cardiol; 2008 Mar; 20(3):99-104. PubMed ID: 18316823
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hidden drugs, hidden risks--is cocaine use a new risk factor for stent thrombosis?
    Lemos PA
    Catheter Cardiovasc Interv; 2007 Jun; 69(7):959-60. PubMed ID: 17525956
    [No Abstract]   [Full Text] [Related]  

  • 19. Neoatherosclerosis: fooling mother nature.
    King SB
    JACC Cardiovasc Interv; 2014 May; 7(5):579-80. PubMed ID: 24852808
    [No Abstract]   [Full Text] [Related]  

  • 20. PCI in small vessels: the case for a drug-coated balloon based intervention.
    Zeymer U; Scheller B
    EuroIntervention; 2011 May; 7 Suppl K():K57-60. PubMed ID: 22027729
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 12.